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Abstracts
 
versely related to patient age (p 
 

 
 .0029), tamoxifen var-
ied directly with patient age (p 
 

 
 .0002) but inversely
with physician age (p  .02), and adjuvant chemotherapy
and taxoids varied inversely with patient age (p  .0001).
CONCLUSIONS: Two decades of multiple randomized
control trials and meta-analyses have led to only modest
success in the use of highly beneficial treatments for
breast cancer in these specific oncology practices, al-
though non-beneficial treatments are almost never used.
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OBJECTIVE:
 
 To evaluate the factors influencing the utiliza-
tion of prescribed medications across the United States.
 
METHODS:
 
 Prescription claims data for a random sam-
ple of commercially insured Express Scripts members, 18
to 64 years of age and continuously eligible for at least
two months in 1999 (N  1,467,699), were geo-coded at
the block group level. Key independent variables included
age, gender, family size, median income, education, ur-
ban/rural location, client type, and pharmacy benefit de-
sign. Outcome measures included any use of prescrip-
tions. Hierarchical modeling (HLM) was used to control
for clustering of patients within health plans.
RESULTS: Results from HLM indicate that after control-
ling for demographics, client type, and pharmacy benefit
design, variation in the probability of using a prescribed
medication was found across regions of the country.
Members in the South have a greater likelihood of use
and members in the Northeast and West having a lower
probability of use than members in the Midwest. A
greater probability of use was associated with older age,
female gender, higher income, family size 1, and enroll-
ment in a managed care plan. Factors associated with
lower probability of prescription use included presence of
a deductible, living in an urban area and having a manda-
tory generic policy.
CONCLUSIONS: While patient age and gender remain
key factors driving prescription utilization, socioeconom-
ics, pharmacy benefit design, and where a person lives are
also predictors of prescription use. Future research is
needed to better understand the causative roles of disease
burden, physician practice style, and consumer preferences
in prescription drug use variation across the United States.
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OBJECTIVE:
 
 The objective of this study was to derive a
brief, clinically relevant symptom index for men with
HRPCa.
 
METHODS:
 
 An international sample of 44 medical on-
cologists, radiation oncologists, and urologists were pre-
sented with 29 disease-related symptoms derived from
the Functional Assessment of Cancer Therapy-Prostate
(FACT-P) quality of life (QOL) instrument and asked to
select the five most important symptoms in assessing the
treatment response for men with HRPCa. Symptoms en-
dorsed at a frequency greater than chance were retained
for the index. Retrospective validation of the index was
accomplished using data from a multi-national, random-
ized, double-blind, placebo-controlled clinical trial of
atrasentan, a selective, oral ET-A receptor antagonist.
The FACT-P and European Organization for Research
and Treatment of Cancer (EORTC) QLQ-C30 adminis-
tered at baseline, six weeks and final visit were used to
evaluate QOL responses to treatment of 288 men with
HRPCa.
RESULTS: Experts initially selected eight priority symp-
toms. Item-Response Theory analysis identified one mis-
fitting item (worry), lending support for a seven-item in-
dex (FPSI-7). Internal consistency was high for the seven-
item index (0.75). Concurrent validity was established
through correlations (P  0.05) between the FPSI-7 and
the FACT-General (FACT-G; r  0.56); FACT-P (r 
0.73); FACT Prostate Cancer Subscale (PCS; r  0.88);
Trial Outcome Index (TOI; r  0.83); and QLQ-C30
global score (r  .56), symptom domain scores (r 
0.33 to 0.76), and generic domain scores (r  0.36 to
0.60). The FPSI-7 successfully differentiated patients by
functional status, measured by the Eastern Cooperative
Oncology Group (ECOG) performance status rating
(PSR, p  .001), and clinical outcome, measured by dis-
ease progression status (p  .001). PSR and disease pro-
gression are important outcomes for patients and clinical
trials. The FPSI-7’s responsiveness to PSR change com-
pared favorably to the FACT-G, PCS, FACT-P and TOI.
CONCLUSION: The FPSI-7 is a valid and responsive
symptom index that can provide efficient, rapid symptom
assessment to evaluate treatment outcome in clinical trials.
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MUCOSITIS IN LYMPHOMA PATIENTS 
RECEIVING HIGH-DOSE CHEMOTHERAPY WITH 
AUTOLOGOUS PBPC TRANSPLANTATION
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OBJECTIVES: To evaluate resource consumption related
to mucositis in lymphoma patients receiving high-dose
chemotherapy (HDC) with autologous PBPC transplan-
tation.
